Strategic-Capacity Buffer Board Challenger

The mandate

Directors keep returning to one unresolved question: which production, tooling, component, technician and depot buffers create an exercisable response during a demand or supply shock, and which merely protect historic footprint or forecast error. Functions use incompatible labels for redundancy, surge, safety stock and strategic reserve. Proposed investments therefore reach the board with compelling disruption stories but little evidence about activation time, customer priority, decay or accountable ownership.

The cadence is three days each month for management-paper review, one challenge session and follow-up with the chair. Five strategy-and-risk committee meetings and three site or supplier-capacity reviews are included in the retainer. A material buffer proposal receives a written question set within two Swiss business days; routine utilisation and service evidence is consolidated into the next monthly session so the adviser does not become an informal approval checkpoint.

The appointment runs for ten months through the annual capital and network plan. In month nine the chair may recommend a separate six-month review only if the board names a new standing question and demonstrates that management has acted on the initial framework. Renewal is not automatic, unused days expire, and a fresh conflict assessment and resolution are required before any later term.

The adviser carries no line authority and no executive responsibility for plants, procurement, service levels, product quality, inventory, capital or customer allocation. Management proposes and operates capacity; directors approve appetite and major commitments. The adviser may press assumptions, compare options and recommend conditions, but cannot approve a buffer, direct a site, select a supplier or declare a reserve available.

Current work for a direct competitor, contract manufacturer, component supplier, hospital purchasing group, logistics provider or resilience-software vendor creates a potential conflict and must be disclosed by category and geography. Relevant commercial interests require recusal from the entire option, not simply price discussion. Compensation cannot depend on capital approved, capacity retained, suppliers selected or a later implementation commission.

Why the board wants this voice

Operations advocates resilience, Finance sees underutilised assets, and commercial leaders invoke patient consequence without a common test of whether capacity can actually be activated. Directors need someone who has both operated constrained medical networks and retired symbolic buffers. The missing voice can connect economics, technical readiness, allocation ethics and recovery time without owning any proposal.

What you will own

• Press management to define each proposed buffer by protected outcome, shock class, activation clock, duration, owner and retirement rule.
• Test whether duplicate tooling, qualified personnel, regulatory approvals, component supply and service parts become available in the same scenario.
• Challenge utilisation measures that hide captive capacity, obsolete variants, untrained shifts, untested suppliers or inaccessible hospital inventory.
• Examine the economic comparison across owned redundancy, reservation contracts, flexible lines, postponement, mutual aid and customer-priority agreements.
• Probe patient-allocation consequences, regulatory limits and communications duties before accepting a claimed emergency production or service response.
• Shape board conditions linking investment release to activation tests, supplier evidence, readiness decay indicators and periodic retirement decisions.
• Give the chair an independent option matrix, unresolved assumptions, conflict record and questions for the annual network approval.

Candidate qualifications

• Governed global medical-device or critical-equipment capacity where quality release, trained labour and service readiness constrained nominal output.
• Has activated a strategic reserve during disruption and can evidence the difference between installed, qualified and truly deployable capacity.
• Retired or redesigned expensive redundancy after demonstrating that its scenario, response time or protected outcome was no longer credible.
• Understands reservation contracts, supplier tooling, postponement, inventory decay, regulatory approvals and customer-allocation consequence together.
• Challenged both operational scarcity narratives and finance utilisation metrics before a board-level capital or network decision.
• Maintained independence from manufacturers, purchasing groups, suppliers, consultants and technology vendors whose options were being compared.

Non-negotiables

• Can attend five Zurich committee sessions and complete three capacity-site or supplier reviews within ten months.
• Will disclose all critical-equipment, contract-manufacturing, hospital, logistics and resilience-vendor interests before papers are shared.
• Brings operating evidence from activated and retired buffers; generic business-continuity governance alone is insufficient.
• Accepts no plant, quality, procurement, allocation, inventory, service, capital or board-voting authority.

1. 49 words maximum. Describe a capacity buffer that appeared available but failed when activation evidence was tested.
2. 49 words maximum. Which manufacturer, supplier or hospital relationship could require recusal from this board’s review?
3. 49 words maximum. What single test best distinguishes resilience capacity from protected underutilisation?